drugset / Trial / NCT02687178

Canrenone as Add-on in Patients With Essential Hypertension

NCT02687178 ↗

Phase 4 Completed 180 enrolled University of Pavia
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy on blood pressure reduction, safety and tolerability of two different dosages of canrenone as add-on therapy in patients already treated with Angiotensin Converting-Enzyme Inhibitors (ACE-I) or Angiotensin II Receptor Blockers (ARBs) and diuretics at the maximum dosage.

Timeline

Start
2010-10
Primary completion
2015-10
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Canrenone Small molecule 50 mg —
Comparator Canrenone Small molecule 100 mg —